Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2011

View Archived Issues

Aspirin lowers risk of colorectal cancer in Lynch syndrome

Recommended phase II dose of serdemetan determined in patients with advanced solid tumors

Fostamatinib shows long-term safety in rheumatoid arthritis

Merck & Co. reports progress of third quarter 2011

Amgen announces highlights of third quarter 2011

Eisai starts phase I trial of candidate insomnia therapy

Enrollment begins in Genetech's phase II GDC-0980 trial in endometrial cancer

Celldex Therapeutics begins phase I trial of CDX-1127

Avir Green Hills Biotechnology reports on flu vaccine

Calcium-activated K(Ca)1.1 potassium channel activator shows promise in model of bladder dysfunction

PROVIDE trial examines boceprevir in patients with refractory hepatitis C

Study assesses dose-response relationship of arthritis therapy

Novel antitumor compound prepared at Chinese university

Access Pharmaceuticals signs agreement for RNAi delivery technology

FDA accepts MoxDuo IR NDA for review

New tranylcypromine derivatives designed in Italy

Children's Hospital Boston and Pfizer to research muscular dystrophy therapeutics

Merck & Co. launches Nexplanon in U.S.

Peking University synthesizes novel agents to treat cancer

Sinovac reports preliminary phase II data on vaccine for hand, foot and mouth disease

Unigene discloses topline phase II data on oral parathyroid hormone analogue

Merck & Co. claims new products for anemia

Dako and BMS build on pharmacodiagnostics collaboration

MIT discloses novel targeted siRNA nanocomplexes for ovarian cancer

Sanofi and Regeneron report on phase II hypercholesterolemia program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...